Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, Reo NV
Journal
FEMS microbiology ecology
Year
2015
Keywords:
NASH, carbohydrate, energy metabolism, gut microbiome, obesity
Obesity is becoming the new pediatric epidemic. Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and has become the most common cause of pediatric liver disease. The gut microbiome is the major metabolic organ and determines how calories are processed, serving as a caloric gate and contributing towards the pathogenesis of NAFLD. The goal of this study is to examine gut microbial profiles in children with NAFLD using phylogenetic, metabolomic, metagenomic and proteomic approaches. Fecal samples were obtained from obese children with or without NAFLD and healthy lean children. Stool specimens were subjected to 16S rRNA gene microarray, shotgun sequencing, mass spectroscopy for proteomics and NMR spectroscopy for metabolite analysis. Children with NAFLD had more abundant Gammaproteobacteria and Prevotella and significantly higher levels of ethanol, with differential effects on short chain fatty acids. This group also had increased genomic and protein abundance for energy production with a reduction in carbohydrate and amino acid metabolism and urea cycle and urea transport systems. The metaproteome and metagenome showed similar findings. The gut microbiome in pediatric NAFLD is distinct from lean healthy children with more alcohol production and pathways allocated to energy metabolism over carbohydrate and amino acid metabolism, which would contribute to development of disease.
Experiment 1
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Subjects
- Location of subjects
- United States of America
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Obesity Adiposis,Adiposity,Obese,Obese (finding),obesity,Obesity (disorder),Obesity [Ambiguous],obesity disease,obesity disorder,Obesity NOS,Obesity, unspecified,Overweight and obesity,Obesity
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- healthy controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- obese without non-alcoholic fatty liver disease
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases. BMI for obese children with and without clinical NAFLD were greater than the 95% for age
- Group 0 sample size Number of subjects in the control (unexposed) group
- 26
- Group 1 sample size Number of subjects in the case (exposed) group
- 11
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Statistical test
- ANOVA
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Source: Table 2
Description: Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease
Abundance in Group 1: increased abundance in obese without non-alcoholic fatty liver disease
| NCBI | Quality Control | Links |
|---|---|---|
| Gammaproteobacteria | ||
| Actinomycetota |
Revision editor(s): WikiWorks
Signature 2
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Source: Table 2
Description: Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease
Abundance in Group 1: decreased abundance in obese without non-alcoholic fatty liver disease
| NCBI | Quality Control | Links |
|---|---|---|
| Clostridia |
Revision editor(s): WikiWorks
Experiment 2
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Non-alcoholic fatty liver disease fatty liver disease, nonalcoholic,fatty liver disease, nonalcoholic, susceptibility to, 1,liver disease, alcoholic, susceptibility to, 1,NAFLD - Nonalcoholic Fatty Liver Disease,NAFLD - nonalcoholic fatty liver disease,NAFLD1,non-alcoholic fatty liver,non-alcoholic fatty liver disease,Nonalcoholic Fatty Liver Disease,nonalcoholic fatty liver disease,Non-alcoholic fatty liver disease
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- non-alcoholic fatty liver disease patients
- Group 1 sample size Number of subjects in the case (exposed) group
- 13
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Source: Table 2
Description: Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD)
Abundance in Group 1: increased abundance in non-alcoholic fatty liver disease patients
| NCBI | Quality Control | Links |
|---|---|---|
| Actinomycetes | ||
| Prevotella | ||
| Fusobacteriia | ||
| Campylobacterota | ||
| Gammaproteobacteria |
Revision editor(s): WikiWorks
Signature 2
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Source: Table 2
Description: Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD)
Abundance in Group 1: decreased abundance in non-alcoholic fatty liver disease patients
| NCBI | Quality Control | Links |
|---|---|---|
| Erysipelotrichia | ||
| Alphaproteobacteria |
Revision editor(s): WikiWorks
Experiment 3
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- obese without non-alcoholic fatty liver disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 11
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Source: Table 2
Description: Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD)
Abundance in Group 1: increased abundance in non-alcoholic fatty liver disease patients
| NCBI | Quality Control | Links |
|---|---|---|
| Actinomycetes | ||
| Prevotella | ||
| Fusobacteriia | ||
| Campylobacterota |
Revision editor(s): WikiWorks
Signature 2
Reviewed Marked as Reviewed by Shaimaa Elsafoury on 2021/02/09
Source: Table 2
Description: Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD)
Abundance in Group 1: decreased abundance in non-alcoholic fatty liver disease patients
| NCBI | Quality Control | Links |
|---|---|---|
| Erysipelotrichia | ||
| Alphaproteobacteria | ||
| Gammaproteobacteria |
Revision editor(s): WikiWorks
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_92&oldid=82609"
Hidden category:
